ShangPharma announced its plans to establish a subsidiary in the Qidong Biopharma Industrial Zone as part of a multistage expansion project for its biologics service portfolio.
In the first phase, Shangpharma and Qidong Biopharma Industiral zone will invest 60 million USD to build a comprehensive and multifunctional pre-clinical research facility as well as a state-of-the-art biologics manufacturing facility. The Preclinical facility will be operated by ShangPharma’s CRO division, ChemPartner and the Biologics manufacturing facility will be operated by Shangpharma’s CMO division, China Gateway Biologics. During the construction phase of the manufacturing facility, the company’s existing biologics CMC facility will continue to operate out of its Shanghai site.
The new China Gateway Biologics’ manufacturing facility will provide commercial scale operations for biopharmaceuticals. It will be comprised of one 500 L single-use mammalian cell culture train for clinical phase supply and two 2000 L trains for commercial manufacturing. These capabilities will be complemented with fill and finish capabilities of the appropriate scale. Michael Hui, CEO of ShangPharma stated, “I am proud that Qidong Biopharma Industrial Zone has selected ShangPharma as partner for the first facility of this kind in Qidong. The investment offers China Gateway Biologics the opportunity to grow to the next level as a full biopharmaceutical service provider from preclinical development to commercial scale. We strongly believe the state-of-the-art single use facility conforming to Western standards will be able to support our international client base.”
Xu Feng, Qidong’s Party Secretary and Chairman of Qidong Standing Committee of the People’s Congress said, “Choosing ShangPharma as the first tenant for the biopharma zone in Qidong is a big milestone to establish Qidong as a biotech hub at the door steps of Shanghai. ShangPharma/CGB is a strong partner with international focus and the facility will serve as model for other projects of similar scale and needs.”
The biopharmaceutical manufacturing facility shall be operational for the first client project in early 2018.